AbCellera Biologics (ABCL) Invested Capital (2020 - 2025)
Historic Invested Capital for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $964.0 million.
- AbCellera Biologics' Invested Capital fell 1222.54% to $964.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $964.0 million, marking a year-over-year decrease of 1222.54%. This contributed to the annual value of $1.1 billion for FY2024, which is 1152.5% down from last year.
- Per AbCellera Biologics' latest filing, its Invested Capital stood at $964.0 million for Q3 2025, which was down 1222.54% from $1.0 billion recorded in Q2 2025.
- AbCellera Biologics' Invested Capital's 5-year high stood at $1.3 billion during Q3 2022, with a 5-year trough of $964.0 million in Q3 2025.
- Moreover, its 5-year median value for Invested Capital was $1.1 billion (2024), whereas its average is $1.1 billion.
- As far as peak fluctuations go, AbCellera Biologics' Invested Capital surged by 3285.11% in 2022, and later tumbled by 1266.28% in 2025.
- Quarter analysis of 5 years shows AbCellera Biologics' Invested Capital stood at $1.0 billion in 2021, then increased by 21.82% to $1.3 billion in 2022, then fell by 5.85% to $1.2 billion in 2023, then dropped by 11.53% to $1.1 billion in 2024, then fell by 9.41% to $964.0 million in 2025.
- Its last three reported values are $964.0 million in Q3 2025, $1.0 billion for Q2 2025, and $1.0 billion during Q1 2025.